🚨 Drug Price Cuts

Today Korean Social News for Beginners | 2026.02.05

0️⃣ Crisis in Pharmaceutical Distribution and Need for System Reform

📌 Frequent drug price cuts cause crisis in distribution industry—calls for system reform grow

💬 The Korea Pharmaceutical Distribution Association held its 64th general meeting and officially raised concerns about worsening conditions in pharmaceutical distribution due to repeated drug price cuts. Each time prices are reduced, distributors must immediately settle even their existing inventory at the lower price, leading to repeated returns, price adjustments, disposal costs, and financial burdens. The distribution industry has requested that the government create a system allowing existing inventory to be billed at pre-reduction prices for a certain period. They also raised issues about increased credit card fees and confusion in distribution order caused by pharmaceutical companies expanding online sales platforms. While drug price cuts benefit patients and health insurance finances, they create structural burdens on distribution sites, highlighting the need for system improvements.

💡 Summary

• Drug price cuts are a system to adjust medicine prices, aiming to reduce health insurance financial burdens.
• Distributors face accumulated burdens from returns and settlements as even inventory is immediately subject to price cuts.
• System review is needed for how prices apply to inventory medicines, distribution margins, and online regulations.

1️⃣ Definition

Drug price cuts refer to a government policy that lowers the insurance ceiling price for medicines covered by health insurance. This is mainly done to reduce health insurance financial burdens and lower patients' medicine costs. The Ministry of Health and Welfare and the Health Insurance Review and Assessment Service comprehensively consider the medicine's effectiveness, substitutability, usage volume, and foreign prices to readjust prices.

Major types of drug price cuts include volume-linked price cuts and generic medicine price reductions. Volume-linked price cuts automatically lower prices when health insurance claims for certain medicines exceed set standards. Generic medicine prices are gradually reduced as competition increases after original medicine patents expire. While these price adjustments have positive effects on reducing national medical costs, they can burden pharmaceutical companies and distributors.

💡 Why is this important?

• Drug price cuts help stabilize health insurance finances and reduce citizens' medical cost burdens.
• The pharmaceutical distribution industry faces accumulated burdens from inventory settlements and cost losses due to repeated price cuts.
• Finding balance between reducing patient burdens and industry sustainability is a key policy challenge.
• Without system improvements, repeated price cuts alone could lead to distribution network collapse and medicine supply instability.

2️⃣ Current Status and Problems with Drug Price Cuts

📕 Background and Operation of Price Cut System

• Health insurance drug price system manages medicine prices. Key details include:

  • Korea manages all medicines by setting health insurance ceiling prices.
  • The Ministry of Health and Welfare sets price standards, and the Health Insurance Review and Assessment Service reviews actual claims.
  • Prices are determined by comprehensively considering effectiveness, substitutability, foreign prices, and manufacturing costs.
  • Prices are not fixed but are periodically readjusted based on increased usage, generic releases, and patent expirations.

• Volume-linked price cuts are frequently applied. Key features include:

  • When health insurance claims for certain medicines exceed set standards, prices are automatically reduced.
  • This mechanism prevents increased medicine usage from increasing financial spending.
  • Mainly targets high-volume chronic disease treatments and generic medicines.
  • Reduction amounts vary based on usage increases, typically 5-10%.

📕 Structural Burdens on Distributors

• Price cuts immediately apply even to inventory medicines. Key problems include:

  • When price cuts are decided, distributors must settle even existing inventory at reduced prices.
  • Distributors face losses from the price difference between high purchase prices and lower selling prices.
  • Medicines already supplied to pharmacies or hospitals require price adjustments to recover differences.
  • This process involves repeated returns, resettlements, and administrative work, increasing labor and time costs.

• Disposal and financial costs accumulate. Key burdens include:

  • If inventory doesn't sell after price cuts, it may need disposal after expiration.
  • Disposal costs are entirely borne by distributors, leading to direct losses.
  • When medicine purchase funds come from financial institution loans, interest burdens increase from price difference losses.
  • More frequent price cuts increase uncertainty in inventory management and fund operations, adding to management burdens.

📕 Additional Factors Worsening Distribution Environment

• Credit card fee burdens are increasing. Key status includes:

  • As credit card payments increase in medicine transactions, fee burdens concentrate on distributors.
  • Since drug prices are government-set fixed prices, fees cannot be reflected in prices, further reducing margins.
  • Especially for low-price generic medicines, situations arise where fees exceed margins, creating negative margins.
  • The distribution industry requests policy support to ease credit card fee burdens.

• Pharmaceutical companies' online platform expansion disrupts distribution order. Key issues include:

  • Cases of pharmaceutical companies directly supplying medicines to pharmacies through their own online distribution networks are increasing.
  • Distribution structures are changing with direct transaction methods bypassing existing distributors.
  • Distributors claim to experience volume decreases and management deterioration.
  • Concerns arise that government lacks clear regulations and order for online distribution, intensifying confusion.

💡 Major Problems with Drug Price Cuts

1. Immediate application: Price difference losses occur as even inventory medicines settle at reduced prices
2. Repeated burdens: Frequent price cuts make returns and settlement work routine
3. Disposal costs: Failed inventory disposal increases losses from expiration
4. Financial burdens: Price difference losses worsen fund operations and increase interest burdens
5. Additional pressures: Credit card fees and online platform expansion further squeeze distribution margins

3️⃣ System Improvement Plans and Future Tasks

✅ Improving How Prices Apply to Inventory Medicines

• Existing inventory should be recognized at pre-reduction prices for a certain period. Key plans include:

  • Allow existing inventory to be billed at pre-reduction prices for a set period (e.g., 3-6 months) from price cut implementation.
  • Enable distributors to receive settlements at purchase-time prices, reducing price difference losses.
  • Guarantee inventory consumption periods to minimize returns and disposal, ensuring distribution stability.
  • Some foreign countries already operate similar grace period systems.

• Frequency and scale of price cuts should be adjusted. Key tasks include:

  • Review standards and cycles for volume-linked price cuts to prevent excessively frequent adjustments.
  • Consider phased adjustments over time rather than large single reductions.
  • Find balance between financial savings and industry sustainability.
  • Government and industry should regularly consult to establish predictable price adjustment systems.

✅ Distribution Margin and Cost Compensation Plans

• Distribution margin realization is needed. Key directions include:

  • Many point out that current pharmaceutical distribution margins don't reflect actual costs.
  • Recalculate appropriate margins reflecting actual costs like logistics, labor, inventory management, and financial costs.
  • Especially improve situations where low-price generic medicines have excessively low margins making distribution difficult.
  • Distribution margin realization is important for securing medicine supply stability.

• Credit card fee burdens should be eased. Key plans include:

  • Negotiate with financial institutions to reduce or exempt credit card fees for medicine transactions.
  • Consider government partial fee support or subsidies to distributors.
  • Improve electronic payment systems to spread payment methods with lower fees.
  • Since drug prices are fixed, fee burdens directly erode margins, requiring active solutions.

✅ Online Distribution Regulation and Order Establishment

• Clear regulations on online pharmaceutical distribution are needed. Key tasks include:

  • Evaluate impact of pharmaceutical companies' own online platform operations on existing distribution order.
  • Diagnose problems of intermediate distribution networks collapsing as direct transactions expand.
  • Establish standards to guarantee quality control, safe storage, and rapid delivery in online distribution.
  • Create fair competition environment between distributors and pharmaceutical companies to build win-win structures.

• Distribution structure efficiency and transparency should be enhanced. Key directions include:

  • Simplify pharmaceutical distribution stages to reduce unnecessary costs and increase efficiency.
  • Strengthen distribution history tracking systems to secure transparent distribution routes.
  • Government should design realistic and executable systems reflecting distribution industry opinions.
  • Balanced policies are needed that both check whether price cut benefits properly reach patients and ease distribution site burdens.

4️⃣ Related Term Explanations

🔎 Health Insurance Drug Price System

• The health insurance drug price system is a framework where the state manages medicine prices.
  • The health insurance drug price system is a system where the government sets and manages insurance ceiling prices for medicines covered by health insurance. Since Korea operates a national health insurance system, nearly all medicines are subject to this system.
  • The price determination process includes: First, when pharmaceutical companies launch new or generic medicines, they apply for price listing with the Ministry of Health and Welfare. Second, the Health Insurance Review and Assessment Service evaluates effectiveness, safety, cost-effectiveness, and foreign prices. Third, the Ministry finalizes and announces prices. Fourth, prices are later readjusted based on increased usage or patent expirations.
  • This system has positive effects of reducing citizens' medical cost burdens and stabilizing health insurance finances. However, concerns arise that excessively low drug prices could lead to management deterioration for pharmaceutical companies and distributors, reduced new drug development investment, and medicine supply instability. The government faces the challenge of finding balance between reducing patient burdens and industry sustainability.

🔎 Volume-Linked Drug Price Cuts

• Volume-linked price cuts automatically lower prices based on usage increases.
  • Volume-linked drug price cuts are a system that automatically reduces drug prices when health insurance claims for certain medicines exceed set standards. This was introduced to prevent increased medicine usage from increasing health insurance financial burdens.
  • The operation method includes: First, the government monitors annual health insurance claims by medicine. Second, when claims exceed reference amounts (e.g., certain percentage increase from previous year), medicines automatically become targets for price cuts. Third, reduction amounts are determined at 5-10% levels based on usage increase degrees. Fourth, reduced prices apply from the following year.
  • While this system has advantages of effectively managing health insurance finances, it acts as an unpredictable burden on pharmaceutical companies and distributors. Especially as chronic disease treatments and generic medicines with high usage volumes frequently become targets, margins for distributors handling these medicines continuously shrink. The industry requests complementary measures like reducing price cut frequency and allowing grace periods for inventory medicines.

🔎 Generic Medicines

• Generic medicines are copy medicines launched after original medicine patents expire.
  • Generic medicines are copy medicines made with the same active ingredients and effects after original medicine (new drug) patents expire. Also called "copy drugs" or "generics," they cost much less because they don't require new drug development costs.
  • Generic medicine characteristics include: First, active ingredients and effects must be identical to originals, passing bioequivalence tests. Second, prices are 30-70% lower than originals. Third, when new drug patents expire, multiple pharmaceutical companies competitively launch generics, further lowering prices. Fourth, they greatly contribute to health insurance financial savings.
  • Korea actively encourages generic medicine use, with prices gradually reduced. Starting at 53.55% of original prices at first launch, additional reductions occur as competitors increase. While generic medicines benefit patients and health insurance, low prices mean small distributor margins, and with credit card fees, negative margins can occur, making distributors sometimes reluctant to handle them.

🔎 Pharmaceutical Distribution Margins

• Pharmaceutical distribution margins are profits distributors earn from supplying medicines.
  • Pharmaceutical distribution margins are profits medicine wholesalers earn through the process of purchasing medicines from pharmaceutical companies and supplying them to pharmacies or hospitals. The difference between purchase and supply prices becomes the distribution margin, which covers logistics costs, labor costs, inventory management costs, and financial costs.
  • Distribution margin reality includes: First, Korea's pharmaceutical distribution margins are around 10%, very low compared to other industries. Second, since drug prices are government-fixed, margins cannot be raised. Third, frequent price cuts further reduce margins. Fourth, credit card fees and rising logistics costs further lower real margins.
  • The distribution industry claims current margins don't reflect actual costs, demanding margin realization. Especially for low-price generic medicines, margins are too low making distribution difficult, with some situations reaching negative margins. Experts point out that government should consider measures to guarantee appropriate distribution margins to secure medicine supply stability.

5️⃣ Frequently Asked Questions (FAQ)

Q: When drug prices are cut, can patients buy medicines cheaper?

A: Yes, for medicines covered by health insurance, out-of-pocket costs decrease with price cuts.

• Drug price cuts lower the medicine prices recognized by health insurance, so patients' out-of-pocket payments at pharmacies also decrease. For example, if a drug price drops from 10,000 won to 9,000 won with a 30% copayment rate, patients pay 300 won less, from 3,000 won to 2,700 won.
• However, for price cut benefits to properly reach patients, the distribution process must function normally. If distributors cannot bear price cut burdens and reduce or stop supplying certain medicines, patients may find it harder to obtain needed medicines. Also, when pharmacies recommend substitute medicines, it's important to verify whether they're actually cheaper. While price cuts benefit patients, they must be balanced with medicine supply stability to lead to real benefits.

Q: Why do distributors lose money from drug price cuts?

A: Because they must sell inventory purchased at higher prices at lower prices.

• Distributors purchase medicines from pharmaceutical companies in advance and hold them as inventory. When price cuts are decided, even existing inventory must immediately settle at reduced prices, causing losses equal to the price difference between purchase and sale prices. For example, if medicines purchased at 10,000 won must be sold at 9,000 won after price cuts, a 1,000 won loss occurs per unit.
• Also, if inventory doesn't sell after price cuts, disposal may be needed after expiration. Since disposal costs are entirely borne by distributors, additional losses occur. Furthermore, repeated returns and price adjustment work increase labor and time costs. The distribution industry requests a system allowing existing inventory to be billed at pre-reduction prices for a certain period. This could help reduce price difference losses and secure distribution stability.

Q: Besides price cuts, what other difficulties does the pharmaceutical distribution industry face?

A: Increased credit card fee burdens and pharmaceutical company online platform expansion are additional pressure factors.

• As credit card payments increase in medicine transactions, credit card fee burdens concentrate on distributors. Since drug prices are government-set fixed prices, fees cannot be reflected in prices, reducing margins by the fee amount. Especially for low-price generic medicines, situations arise where fees exceed margins, creating negative margins. The distribution industry requests credit card fee reductions or government support.
• Also, cases of pharmaceutical companies directly supplying medicines to pharmacies through their own online distribution networks are increasing. As direct transaction methods bypassing existing distributors spread, distributors experience volume decreases and management deterioration. The distribution industry requests clear regulations on online distribution and creation of fair competition environments. With credit card fees and online platform expansion added to price cuts, burdens on distribution sites intensify, requiring comprehensive system review.

Table of Contents

• Go to Guide